#1 Clinical Trials Search in Europe

HUPERZINE A

Clinical trials are investigating HUPERZINE A in adults with focal onset seizures. This article explains what the study is testing, who may take part, and which outcomes are being measured, such as seizure frequency and treatment effect.

Table of contents

Trial overview

The available clinical trial is studying HUPERZINE A in adults with focal onset seizures.[1]

The study is designed to evaluate whether HUPERZINE A may help reduce seizure frequency in this patient group.[1]

Study design and treatment groups

This is a Phase 2 trial, which means it is a later early-stage study that looks at whether a treatment may work in a specific condition.[1]

The study is double-blind and placebo-controlled.[1]

Double-blind means the participants and the study team do not know who receives which treatment, and placebo-controlled means some participants receive capsules without the active study drug.[1]

The intervention list includes oral HUPERZINE A at 0.25 mg, 0.50 mg, and 1.00 mg, as well as capsules used for comparison.[1]

Who can participate

The trial is for adult participants with focal onset seizures.[1]

No other participation details are provided in the source data, so the full eligibility rules cannot be described here.[1]

What the study is measuring

The primary outcome is the percent change from baseline in focal onset seizure frequency per 28 days during the maintenance period.[1]

This means the researchers will compare the number of seizures before treatment with the number during the study period to see whether seizures become less frequent.[1]

The brief summary says the goal is to evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures.[1]

Trial status and size

The study status is Authorised.[1]

The planned enrollment is 45 people, which means the study is designed to include 45 participants.[1]

Because only one trial is listed in the source data, this article reflects a very limited trial set and focuses on the main details available for that study.[1]

Trial IDPhaseCondition studiedStatusEnrollment
2025-520587-18-00Phase 2Focal Onset SeizuresAuthorised45

FAQ

  • What is being studied in the HUPERZINE A trial? The trial is studying HUPERZINE A as a treatment for adults with focal onset seizures. It compares different oral doses with capsules used as a control.
  • Who can take part in this study? The study is for adult participants with focal onset seizures. Other detailed entry rules are not provided in the trial data.
  • What phase is the HUPERZINE A trial? This is a Phase 2 study. Phase 2 trials usually look at whether a treatment may work in a specific condition and continue to collect safety information.
  • What outcome is the study measuring? The main outcome is the percent change in focal onset seizure frequency per 28 days during the maintenance period. This helps show whether seizures become less frequent over time.
  • Is the study blinded and controlled? Yes. The trial is double-blind and placebo-controlled. Double-blind means neither the participants nor the study team know who gets which treatment, and placebo-controlled means some participants receive capsules without the active study drug.

Ongoing Clinical Trials on HUPERZINE A

  • Study of SPN-817 (Huperzine A) in Adults with Focal Onset Seizures: Testing Safety and Effectiveness of Treatment

    Not yet recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Hungary Poland

Glossary

  • Focal onset seizures: Seizures that start in one area of the brain before they may stay there or spread. The study is focused on adults with this condition.
  • Phase 2: A mid-stage clinical trial that mainly checks whether a treatment may work and continues to watch for safety.
  • Double-blind: A study design where neither the participant nor the study team knows who is receiving the active treatment. This helps reduce bias.
  • Placebo-controlled: Some participants receive a placebo, which looks like the study treatment but does not contain the active drug. This helps compare results fairly.
  • Interventional study: A study where researchers give a treatment and then measure what happens.
  • Enrollment: The number of people planned to join the study.
  • Primary outcome: The main result the researchers want to measure to see if the treatment works.
  • Baseline: The starting point before treatment begins. Results are often compared with this starting point.
  • Maintenance period: The part of the study when the treatment effect is measured over time after the initial treatment period.
  • Percent change: A way to show how much a number has gone up or down compared with the start of the study.

References

  1. https://clinicaltrials.gov/study/2025-520587-18-00